SION - NASDAQ
Sionna Therapeutics, Inc.
$36.70
-10%Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
At a Glance
Live SnapshotSionna Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Sionna Therapeutics, Inc. Cash Flow Statement
SION • NASDAQ
| Sionna Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-75.3M | -61.7M | -47.3M | -40.2M | |
-3.1M | 668K | 583K | 122K | |
12.1M | 3.7M | 2.3M | 1.7M | |
2.6M | 7.6M | 1.5M | -400K | |
-2.7M | -3.1M | -783K | 2.8M | |
-66.3M | -52.8M | -43.7M | -36.1M | |
INVESTING ACTIVITIES | ||||
-377K | -27K | -1.1M | -1.9M | |
-325M | -182.8M | -23.5M | -40.4M | |
206.7M | 56M | 52M | 13M | |
-118.7M | -126.9M | (27.4M) | -29.3M | |
FINANCING ACTIVITIES | ||||
205.7M | 179M | 0.0 | 0.0 | |
0.0 | 0.0 | 31K | 64K | |
205.7M | 179M | 31K | 110.9M | |
CASH FLOW SUMMARY | ||||
20.7M | -733K | -16.3M | 45.5M | |
38.8M | 39.5M | 55.8M | 10.3M | |
59.4M | 38.8M | 39.5M | 55.8M | |
-66.7M | -52.8M | -44.8M | -37.9M |
SEC Filings
SION - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 11, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 11, 2025 | August 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 13, 2025 | June 12, 2025 | 2025 |
Related Guides
Continue your SION research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.